SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SRGN ( Seragen, Inc.) -- Ignore unavailable to you. Want to Upgrade?


To: Dr. John M. de Castro who wrote (28)2/7/1998 12:47:00 AM
From: AL RICE  Respond to of 52
 
John,
I talked with Lora at Seragin and she also said what you have just expressed. She says," Nothing new "

al



To: Dr. John M. de Castro who wrote (28)2/7/1998 9:58:00 AM
From: Cosmo Daisey  Respond to of 52
 
Dr. John,
The progress towards a marketable product is what has the market interested in SRGN. Once approval is granted, then other uses will be registered also. The relatively small float should bring higher prices than what we saw this week as the company begins to deliver on the promises they made years ago.
CD



To: Dr. John M. de Castro who wrote (28)3/31/1998 11:34:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 52
 
Recent SEC filing indicates that the SRGN compound that LLY has agreed to license to LGND for CTCL is DAB-IL-2.